经皮雌二醇用于雄激素剥夺治疗所致男性乳房发育:真实情况与主观恐惧
本文汇总5项涉及480例遗传男性(跨性别女性)接受外源性雌二醇治疗的研究,发现其乳房发育通常小于A罩杯且多发生在治疗第一年。据此推断前列腺癌患者选择经皮雌二醇行雄激素剥夺治疗时乳房发育程度较轻,可缓解患者和泌尿肿瘤医生的过度担忧。乳房痛常见但多为一过性,可局部抗炎药或神经切除术管理。
要点
- 外源性雌二醇所致乳房发育通常小于A罩杯,多发生于治疗第一年。
- 前列腺癌患者选择经皮雌二醇行ADT时乳房发育程度预计较轻。
- 乳房痛常见但多为一过性,可局部抗炎药或神经切除术管理。
核心结论
- 遗传男性接受外源性雌二醇时乳房组织发育通常较轻,多小于A罩杯。
- 前列腺癌患者选择经皮雌二醇行ADT时乳房发育程度预计较轻,可缓解过度担忧。
- 乳房痛常见但多为一过性,可局部抗炎药或神经切除术管理。
研究设计与样本
- 汇总5项研究,共480例遗传男性(跨性别女性)接受外源性雌二醇性别肯定激素治疗。
主要发现
- 外源性雌二醇通常诱导跨性别女性乳房发育小于A罩杯。
- 大部分乳房发育发生在治疗第一年内。
- 前列腺癌患者使用雌二醇时乳房和乳头敏感常见但多为一过性。
临床怎么用
- 可利用上述证据为前列腺癌患者提供关于经皮雌二醇行ADT所致乳房发育的准确咨询。
- 乳房痛可尝试局部抗炎药,严重病例可考虑神经切除术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To provide information that can aid patients with prostate cancer (PCa) and their uro-oncologists in shared decision-making discussions about androgen deprivation therapy (ADT), with transdermal oestradiol (tE2) as one option. We do so by summarising recent literature on breast growth in genetic males undergoing treatment with exogenous E2. Based on the amount of breast development observed in this population, we estimate the maximum amount of breast growth that patients with PCa can expect, if they elect tE2 for ADT. We also present data on risks and management of mastalgia associated with tE2. METHODS: We summarise findings from five studies involving a total of 480 trans women (i.e., genetic males) undergoing gender-affirming hormone treatment with exogenous oestrogen. RESULTS: Exogenous E2 typically induces less than an A-cup size among trans women. The majority of breast growth occurs within the first year of treatment. We present this evidence to illustrate that the degree of gynaecomastia patients with PCa can expect if they elect tE2 for ADT is quite modest. This information can allay the often-heightened concern patients with PCa and their uro-oncologists may have regarding gynaecomastia induced by tE2 when used for ADT. CONCLUSION: Development of breast tissue in genetic males taking exogenous E2 tends to be mild and typically results in less than A-cup size. Mastalgia in the form of breast and nipple sensitivity is common with E2 treatment in patients with PCa but is transient in most cases, responds to topical anti-inflammatory agents, and can be managed with neurectomy in severe cases. This information can help clinicians provide accurate counselling and mitigate misconceptions that may dissuade patients from considering tE2 for their ADT.
引用
- Sears C, Watson R, Brown E, et al. Gynaecomastia secondary to transdermal oestradiol used for androgen deprivation therapy: informed reality vs subjective fear. BJU Int. 2026. PMID: 42446241. doi:10.1111/bju.70374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。